Moderna
MRNA · Nasdaq · Health Care
☆ Follow
Shareholder advocacy aimed at Moderna
2 recorded campaigns from 2 organizations.
Oxfam at Moderna
Study the feasibility of transferring vaccine technology and know-how so that production can be scaled up and access improved around the world.
Oxfam America at Moderna
Study the feasibility of sharing Moderna's mRNA COVID-19 vaccine technology and know-how with resource-poor countries to expand global manufacturing and access.
What shareholders voted on
From Moderna’s own filings with the SEC. Support is the share of votes cast for and against, so abstentions and broker non-votes are not counted in it.
2026
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Stockholders’ vote with respect to the approval of the compensation of the named executive officers was as follows | Say on pay | 65.1% | Passed | |
| Abbas Hussain | Company proposal | 98.5% | Passed | |
| Sandra Horning, M.D | Company proposal | 81% | Passed | |
| The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, with the votes cast as follows | Auditor | 98.9% | Passed |
2025
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Stockholders’ vote with respect to the approval of the compensation of the named executive officers was as follows | Say on pay | 77.3% | Passed | |
| The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025, with the votes cast as follows | Auditor | 98.9% | Passed | |
| Election of Stéphane Bancel | Director | 97.9% | Passed | |
| Election of Noubar Afeyan | Director | 87.2% | Passed | |
| Election of François Nader | Director | 78% | Passed |
2024
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Stockholders’ vote with respect to the approval of the compensation of the named executive officers was as follows | Say on pay | 90.5% | Passed | |
| An amendment to the Charter to provide stockholders the right to call a special meeting, as described in Item 5.03 | Company proposal | 99.8% | Passed | |
| Elizabeth Nabel, M.D | Company proposal | 97% | Passed | |
| An amendment to the Charter to reflect new Delaware law provisions regarding officer exculpation, as described in Item 5.03 | Company proposal | 96.6% | Passed | |
| The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024, with the votes cast as follows | Auditor | 99.5% | Passed | |
| Election of Elizabeth Tallett | Director | 94.3% | Passed | |
| Election of Robert Langer | Director | 80.2% | Passed |
2023
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Shareholder proposal requesting a report on feasibility of transferring intellectual property | Shareholder proposal | 7.4% | Failed | |
| Sandra Horning, M.D | Company proposal | 96.9% | Passed | |
| The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, with the votes cast as follows | Auditor | 98.9% | Passed | |
| Election of Stephen Berenson | Director | 77.9% | Passed | |
| Election of Paul Sagan | Director | 75.3% | Passed |
2022
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Shareholder proposal requesting a report on feasibility of transferring intellectual property | Shareholder proposal | 23.8% | Failed | |
| Stéphane Bancel | Company proposal | 82.4% | Passed | |
| François Nader, M.D | Company proposal | 78.2% | Passed | |
| Noubar Afeyan, Ph.D | Company proposal | 77.3% | Passed | |
| The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022, with the votes cast as follows | Auditor | 75.7% | Passed |
2021
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Elizabeth Tallett | Company proposal | 91.8% | Passed | |
| Elizabeth Nabel, M.D | Company proposal | 87.4% | Passed | |
| Robert Langer, SC.D | Company proposal | 81.3% | Passed | |
| The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021, with the votes cast as follows | Auditor | 98.4% | Passed |
2020
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Sandra Horning, M.D | Company proposal | 99.6% | Passed | |
| The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020, with the votes cast as follows | Auditor | 99.9% | Passed | |
| Election of Paul Sagan | Director | 92.5% | Passed | |
| Election of Stephen Berenson | Director | 91.9% | Passed |
2019
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Stéphane Bancel | Company proposal | 98.8% | Passed | |
| Noubar Afeyan, Ph.D | Company proposal | 98.6% | Passed | |
| Peter Barton Hutt, LL.M | Company proposal | 93.5% | Passed |
Proxy statements and vote results
Straight from Moderna’s own SEC filings. The proxy statement lists what shareholders were asked to vote on; the 8-K certifies how the vote went.
| Year | Filing | Filed |
|---|---|---|
| 2026 | Vote results | 2026-05-11 |
| 2026 | Proxy statement | 2026-03-16 |
| 2025 | Vote results | 2025-11-13 |
| 2025 | Proxy statement | 2025-10-15 |
| 2025 | Vote results | 2025-05-05 |
| 2025 | Proxy statement | 2025-03-11 |
| 2024 | Vote results | 2024-05-09 |
| 2024 | Proxy statement | 2024-03-21 |
| 2023 | Vote results | 2023-05-05 |
| 2023 | Proxy statement | 2023-03-15 |
| 2022 | Vote results | 2022-05-03 |
| 2022 | Proxy statement | 2022-03-09 |
| 2021 | Vote results | 2021-04-29 |
| 2021 | Proxy statement | 2021-03-10 |
| 2020 | Vote results | 2020-05-01 |
| 2020 | Proxy statement | 2020-03-16 |
| 2019 | Vote results | 2019-06-27 |
| 2019 | Proxy statement | 2019-05-15 |
Do you represent Moderna? Claim this profile to respond to the campaigns listed here.